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Introduction: Mesenchymal stem cells (MSCs) are promising candidates for cell-based therapies. Human platelet
lysate represents an efficient alternative to fetal bovine serum for clinical-scale expansion of MSCs. Different media
used in culture processes should maintain the biological characteristics of MSCs during multiple passages. However,
bone marrow-derived MSCs and adipose tissue-derived MSCs have not yet been directly compared with each other
under human platelet lysate conditions. This study aims to conduct a direct head-to-head comparison of the biological
characteristics of the two types of MSCs under human platelet lysate-supplemented culture conditions for their ability
to be used in regenerative medicine applications.
Methods: The bone marrow- and adipose tissue-derived MSCs were cultured under human platelet lysate conditions
and their biological characteristics evaluated for cell therapy (morphology, immunophenotype, colony-forming
unit-fibroblast efficiency, proliferation capacity, potential for mesodermal differentiation, secreted proteins, and
immunomodulatory effects).
Results: Under human platelet lysate-supplemented culture conditions, bone marrow- and adipose tissue-derived
MSCs exhibited similar fibroblast-like morphology and expression patterns of surface markers. Adipose tissue-derived
MSCs had greater proliferative potential than bone marrow-derived MSCs, while no significantly difference in colony
efficiency were observed between the two types of cells. However, bone marrow-derived MSCs possessed higher
capacity toward osteogenic and chondrogenic differentiation compared with adipose tissue-derived MSCs, while similar
adipogenic differentiation potential wase observed between the two types of cells. There were some differences
between bone marrow- and adipose tissue-derived MSCs for several secreted proteins, such as cytokine (interferon-γ),
growth factors (basic fibroblast growth factor, hepatocyte growth factor, and insulin-like growth factor-1), and chemokine
(stem cell-derived factor-1). Adipose tissue-derived MSCs had more potent immunomodulatory effects than bone
marrow-derived MSCs.
Conclusions: Adipose tissue-derived MSCs have biological advantages in the proliferative capacity, secreted proteins
(basic fibroblast growth factor, interferon-γ, and insulin-like growth factor-1), and immunomodulatory effects, but bone
marrow-derived MSCs have advantages in osteogenic and chondrogenic differentiation potential and secreted proteins
(stem cell-derived factor-1 and hepatocyte growth factor); these biological advantages should be considered
systematically when choosing the MSC source for specific clinical application.* Correspondence: 13811647091@163.com
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Mesenchymal stem cells (MSCs) hold great promise in
the field of regenerative medicine based on their abilities
of self-renewal and multilineage differentiation [1]. Over
the past decade, MSCs which are isolated from the um-
bilical cord, umbilical cord blood, bone marrow (BM),
adipose tissue (AT) and many other adult tissues have
been explored as potential therapeutic strategies for a
number of diseases [2], but AT and BM are the most
widely used sources of MSC, especially in autologous
cell-based therapies due to ease of harvest and potential
autologous application [3]. Moreover, there are a relative
abundance of progenitors and a lack of ethical concerns.
However, one important question that remains to be an-
swered is which cell is more effective and suitable for
cell therapy. Many studies have shown that BMMSCs
and ATMSCs share similar features, including the mor-
phologic features and the expression of cell surface anti-
gens, but significant biologic differences have been
observed concerning their proliferation rates and differ-
entiation capacities [4-9]. Conflicting results have been
reported, with some indicating that the clinical applica-
tion potential of ATMSCs is more effective or as effect-
ive as that of BMMSCs, while others conclude that
BMMSCs are superior to ATMSCs [7,10-13]. Moreover,
there are significant differences between ATMSCs and
BMMSCs in the cytokine secretome and chemokine re-
ceptor expression [10,14,15], which may provide clues to
alternative cell sources. One study has demonstrated
that ATMSCs are more resistant to in vitro apoptosis
than BMMSCs [11].
In these studies, comparative analysis of BMMSCs and
ATMSCs is performed in medium supplemented with
fetal bovine serum (FBS). FBS is an animal source prod-
uct, and its use is undesirable due to potential transmis-
sion of animal pathogens and the risk that antibodies
against FBS are developed, leading to rejection of the
transfused cells [16]. In fact, as much as 20 to 50% of
commercial FBS is virus-positive [17]. It has been shown
that a single preparation of 108 MSCs grown in FBS can
carry approximately 7 to 30 mg FBS proteins [18]. At
present, the main alternative to FBS-supplemented
medium is the use of human reagents enriched with
growth factors, namely human platelet lysate (hPL),
which increases safety by excluding xenogeneic proteins.
The usage of hPL in MSC culture provides the follow-
ing advantages: 1) hPL as a human reagent lacks any risk
of secondary effects which may be caused by FBS con-
stituents in culture [19]; and 2) platelet rich plasma
(PRP) as a source of hPL can be directly implemented
for clinical applications since it is Good Manufacturing
Practice-approved without extensive testing [20,21].
Several previous studies have been conducted to com-
pare the biological characteristics of BMMSCs andATMSCs between two different supplemented culture
conditions (FBS versus hPL) [20,22-26]. Based on effi-
ciency and safety, hPL can replace FBS for clinical-scale
expansion of functional BMMSCs and ATMSCs for
therapeutic applications. Most of the studies report that
the growth factor-enriched hPL has considerable
growth-promoting properties for MSCs while maintain-
ing their immunophenotype, differentiation potential
and immunomodulatory properties [20,23,26]. However,
one study reports that MSCs show an increase in osteo-
genic differentiation and a decrease in adipogenic differ-
entiation when cultured in hPL-supplemented medium
[26]. Moreover, a report illustrates that hPL alters the
expression of some relevant MSC surface molecules and
leads to a decreased inhibitory capacity on T cell and
natural killer cell proliferation and function compared to
FBS [27].
Therefore, the medium used is crucial for the safety
and efficacy of MSC culture, and different media used in
the culture processes should maintain the different
phenotype, differentiation potential, and functions of
MSCs during multiple passages [28]. However, BMMSCs
and ATMSCs have not yet been directly compared with
each other under hPL conditions for their ability to be
used in regenerative medicine applications.
Increasing evidence supports the generalization that
stem cell therapy produces generally positive effects largely
via secretion of various cytokines, such as growth factors,
cytokines and chemokines, involving anti-scarring, anti-
apoptotic, angiogenesis, immunomodulatory and chemo-
attractant functions [29-31].
The aim of this study is to conduct a direct head-to-
head comparison of the following biological characteristics
of the two types of MSC: morphology, immunophenotype,
colony-forming unit-fibroblast (CFU-F) efficiency, prolif-
eration capacity, potential for mesodermal differentiation,
and expression of several well-characterized growth fac-
tors, cytokines and chemokines in vitro. To the best of
our knowledge, this is the first study that directly com-
pares human BMMSCs and ATMSCs under hPL condi-
tions. Such information may be crucial for identifying a
more suitable cell source for a given clinical application.
Materials and methods
Medium preparations
hPL was prepared as previously described [32]. Briefly,
PRP, obtained from one healthy volunteer at the Hospital
Transfusion center, was standardized to a concentration
of approximately 1 × 109 platelets/mL, and then PRP was
frozen down to −80°C and subsequently thawed at 37°C
to obtain platelet-released growth factors. Lysed PRP
(20 units) was pooled to avoid individual donor varia-
tions. hPL was centrifuged at 4,000 g for 15 minutes at
4°C to remove the platelet fragments. The supernatant
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Biosciences, San Jose, CA, USA) and added to heparinized
Iscove’s modified Dulbecco’s medium (IMDM; 2 U/mL).
Human bone marrow- and adipose tissue-derived
mesenchymal stem cell cultures
All samples were obtained from healthy donors with in-
formed consent, and the study was approved by the
Ethics Committee of Military 302 Hospital of China.
BMMSC cultures were established as previously de-
scribed [8]. Briefly, BM aspirates (25 mL) were collected
from five volunteers aged 18 to 30 years. BM was layered
over a lymphoprep gradient and centrifuged at 2,000 rpm
for 30 minutes. Mononuclear cells were washed twice with
phosphate-buffered saline (PBS) and plated at a concen-
tration of 2 × 105/cm2 in 75 cm2 flasks for 2 days in 5%
hPL-supplemented medium. After removing nonadherent
cells, the adherent cells were maintained at 37°C, 5% CO2.
The medium was subsequently changed twice a week.
ATMSCs were isolated by enzymatic digestion as previ-
ously described [33]. Briefly, lipoaspirate tissues (25 mL)
were harvested from five volunteers and washed with PBS
in a 50-mL Falcon tube. The tissues were then digested
with an equal volume of 0.2% collagenase type IV at 37°C
for 30 minutes, and the stromal vascular fraction cells iso-
lated by centrifugation at 300 × g at room temperature.
Viable cells (1 × 106) were cultured in 75 cm2 flasks in 5%
hPL-supplemented medium. After 2 days, the unattached
cells were depleted by replacing the medium with fresh
medium. The medium was subsequently changed twice a
week.
At 80 to 90% confluence, both types of cells were har-
vested with trypsin-ethylenediaminetetraacetic acid and
subsequently replated at 2,000 cells/cm2.
Proliferation studies
To compare the proliferative potential of BMMSCs and
ATMSCs, both types of cells were serially passaged and
counted when a subconfluence of 80 to 90% was
reached. The mean population doubling (PD) was deter-
mined for each passage using the following formula:
PD ¼ log10 Nhð Þ− log10 Npð Þ½ 
log10 2ð Þ
where Nh is the collected cell number and Np is the
plated cell number. The PD for each passage was added
to the PD of the previous passages to give cumulative
population doubling (CPD).
Colony-forming unit-fibroblast assays
To assess the capacity for self-renewal of BMMSCs and
ATMSCs, the CFU-F assay was performed as previously
described [34]. Briefly, single-cell suspensions at passage1 were plated in six-well culture plates in IMDM (5%
hPL) at densities of 1 × 103 per well. On day 14, the cell
layer was fixed with methanol and stained with crystal
violet. Individual colonies composed of at least 50 cells
were counted.
Flow cytometry analysis
For the analysis of surface marker expression of
BMMSCs and ATMSCs, both types of cells at passage 5
were washed three times with PBS, and then incubated
with a blocking solution of 3% serum in PBS for 30 mi-
nutes. After centrifugation, 5 × 105 cells were suspended
in blocking solution, then stained with antibodies against
human CD14, CD19, CD90, CD105, HLA-DR, CD29,
CD13, CD34, CD45 and HLA-ABC (BD Biosciences).
After incubation for 30 minutes, the cells were washed
with PBS, and then analyzed by flow cytometry on a
FACSCalibur (Becton Dickinson, San Jose, CA, USA)
following standard procedures.
Multilineage differentiation and staining assay
To assess the differentiation potential of BMMSCs and
ATMSCs, both types of cells at passage 5 were differen-
tiated into adipocyte, osteoblast, and chondrocyte
phenotypes.
For osteogenic differentiation, BMMSCs and ATMSCs
were seeded at 5 × 103 cells/cm2 for 24 hours, and then
cultured in the osteogenic differentiation medium con-
taining 5% hPL, 100 nM dexamethasone, 50 μM
ascorbate-2-phosphate, and 10 mM β-glycerophosphate
in Dulbecco's modified Eagle's medium (DMEM). The
differentiation medium was subsequently changed twice
a week. After 21 days, osteogenic differentiation was
assessed by Alizarin Red staining of calcium phosphate
deposits.
For adipogenic differentiation, BMMSCs and ATMSCs
were seeded at 2 × 104 cells/cm2 for 24 hours, and then
cultured in the adipogenic differentiation medium con-
taining 5% hPL, 1 μM dexamethasone, 0.2 mM indo-
methacin, 0.5 mM isobutyl-1-methylxanthine, and
10 mg/L insulin in DMEM. The differentiation medium
was subsequently changed twice a week. After 21 days,
adipogenic differentiation was assessed by Oil Red O
staining of the fatty vacuoles.
For chondrogenic differentiation, 5-μl droplets of cell
solution of 2 × 107 cells/mL were seeded in the center of
a multi-well plate to form a micromass cultures for
2 hours, and then cultured in the chondrogenic differen-
tiation medium containing 10 mg/L insulin, 10 mg/L
transferrin, 5 μg/L sodium selenite, 100 nM dexametha-
sone, 50 mg/L ascorbate-2-phosphate, 20 ng/mL trans-
forming growth factor (TGF)-β3, 40 mg/L L-proline,
3 mM linoleic acid, 3 mM oleic acid, and 4 g/L human
serum albumin in DMEM. The differentiation medium
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chondrogenic differentiation was assessed by Alcian Blue
staining of sulfated proteoglycans.
Real-time polymerase chain reaction analysis
Real-time PCR was performed to detect the gene expres-
sion indicative of cell differentiation. Table 1 lists the
primers that were used. Power SYBR Green PCR Master
mix (Applied Biosystems, Fostrt City, CA, USA) was used
under the following conditions: 50°C for 2 minutes, 95°C
for 2 minutes, and then 95°C for 3 seconds and 60°C for
30 seconds for a total of 40 cycles. Results were analyzed
using the 2-ΔCt method relating gene expression to β-actin.
Enzyme-linked immunosorbent assay
To compare protein secretion between BMMSCs and
ATMSCs, the production of inflammatory cytokines (such
as tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and
interleukin (IL)-6), chemokines (such as stem cell-derived
factor-1 (SDF-1) and IL-8), and growth factors (such as
basic fibroblast growth factor (bFGF), hepatocyte growth
factor (HGF), insulin-like growth factor (IGF)-1, and vascu-
lar endothelial growth factor (VEGF)) were measured. Both
types of cells (1 × 105 cells/well) at passage 5 were seeded
on 24-well culture plates in hPL-free IMDM medium for
48 hours. The supernatants were collected, and the concen-
trations were measured with human enzyme-linked im-
munosorbent assay (ELISA) kits (R&D, Minneapolis, MN,
USA), according to the manufacturer’s instructions.
Mixed lymphocyte culture assays
To quantify and compare the immunomodulatory effects
of BMMSCs and ATMSCs, both types of cells were firstTable 1 Primer sequences for real-time PCR analysis and
their respective product sizes

















CTGGAAGGTGGACAGCGAGGtreated with mitomycin C (50 μg/ml for 50 minutes) to
inactivate the proliferation. Next, human peripheral
blood mononuclear cells were prepared by centrifuga-
tion on a Ficoll-Hypaque density gradient, and 2 × 105
cells of mononuclear cells were co-cultured with 2 × 103,
5 × 103, and 1 × 104 BMMSCs and ATMSCs per well in
96-well culture plate with 1 μg/ml anti-CD3 and anti-
CD28 T-cell activating mAbs (Life Technologies,
Carlsbad, CA, USA) for 72 hours at 37°C and 5% CO2.
Conditioned medium was collected for the evaluation of
indoleamine 2,3-dioxygenase (IDO) activity and prosta-
glandin E2 (PGE2) and TGF-β quantification. PGE2 and
TGF-β concentrations were quantified using ELISA
(R&D), according to the manufacturer’s instructions.
IDO activity was evaluated by Kynurenine levels as pre-
viously described [35]. Kynurenine levels are directly
proportional to IDO activity.
Statistical analysis
The data are presented as the means ± standard devia-
tions of at least three experiments. Statistical analyses
between groups were carried out using a Student’s t-test.
P < 0.05 was considered to indicate a statistically signifi-
cant difference.
Results
Morphology of bone marrow- and adipose tissue-derived
mesenchymal stem cells
The adherent cells from BM and AT formed several col-
onies and exhibited a heterogeneous morphology with
various shapes, including discoidal flat, triangular, and
elongated. After passage 3, both types of cells became
relatively homogeneous and showed a similar fibroblast-
like (elongated spindle) morphology with abundant cyto-
plasm and large nuclei. BMMSCs and ATMSCs grew in
parallel or vortex-like patterns, and no morphologic dif-
ferences were observed in the final cell morphology
(Figure 1).
Proliferation capacity of bone marrow- and adipose
tissue-derived mesenchymal stem cells
CPD analysis showed that ATMSCs possessed higher
CPD numbers for each passage, compared with BMMSCs
(all P < 0.05), indicating that ATMSCs had greater prolifer-
ative potential than BMMSCs (Figure 2A). At passage 5,
CPD of ATMSCs and BMMSCs reached 13.7 ± 0.5 and
17.2 ± 0.3, respectively (P < 0.01).
CFU-F analyses showed no significant difference in col-
ony counts between BMMSCs and ATMSCs (P > 0.05;
Figure 2B), although ATMSCs proliferated more rapidly
than BMMSCs. Moreover, there were no significant differ-
ences in the cell number of each colony between
BMMSCs and ATMSCs (data not shown).
Figure 1 Morphology of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells cultivated in human platelet
lysate-supplemented medium. BMMSCs and ATMSCs were tiny, slender, and bright. Scale bar = 100 μm.
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adipose tissue-derived mesenchymal stem cells
Flow cytometry analysis showed that BMMSCs and
ATMSCs expanded in hPL-supplemented medium exhib-
ited specific MSC markers (CD13, CD105) and cell adhe-
sion molecules (CD29, CD90) at high levels (>85%), and
hematopoietic cell markers (CD14, CD19, CD34, CD45)
molecules at very low levels (<0.5%). Moreover, both types
of cells expressed HLA-ABC (>85%) but not HLA-DR
(<0.5%) (Table 2). A representative phenotypic analysis of
BMMSCs and ATMSCs is shown in Figure 3, demonstrat-
ing the homogeneity of the phenotype. In summary,
BMMSCs and ATMSCs in hPL-supplemented medium
reveal very similar expression patterns of surface markers.
Differentiation of bone marrow- and adipose tissue-derived
mesenchymal stem cells into osteocytes, chondrocytes and
adipocytes
To explore the differentiation potential towards osteo-
blasts, adipocytes, and chondrocytes of BMMSCs and
ATMSCs expanded in hPL-supplemented medium, cyto-
chemical staining and real-time PCR were performed to
detect the cell differentiation capacity.
Calcium deposits of BMMSCs and ATMSCs after
21 days of differentiation were visualized by Alizarin Red
staining, but the amount of staining was higher in
BMMSCs than that in ATMSCs (Figure 4A). Furthermore,
BMMSCs differentiated toward osteoblasts showed astatistically significant higher expression of RUNX-2
and alkaline phosphatase than ATMSCs (both P < 0.05;
Figure 4B). This indicates that BMMSCs have a higher
osteogenic capability compared with ATMSCs.
Sulfated proteoglycans of BMMSCs and ATMSCs after
21 days of differentiation were visualized by Alcian Blue
staining, but the amount of staining was higher in
BMMSCs than that in ATMSCs (Figure 5A). Further-
more, BMMSCs differentiated toward chondrocytes
showed a statistically significant higher expression of
SOX-9 and collagen II than ATMSCs (both P < 0.01;
Figure 5B). This indicates that BMMSCs have a higher
chondrogenic capability compared with ATMSCs.
Fatty vacuole deposits of BMMSCs and ATMSCs after
21 days of differentiation were visualized by Oil Red O
staining; no significant differences in the amount of stain-
ing were observed between two types of cells (Figure 6A).
Furthermore, the BMMSCs differentiated toward adipo-
cytes showed statistically similar mRNA expression of
PPARγ and LPL as ATMSCs (both P > 0.05; Figure 6B).
This indicates that BMMSCs and ATMSCs have similar
adipogenic capability.
Expression analysis of cytokines, growth factors, and
chemokines of bone marrow- and adipose tissue-derived
mesenchymal stem cells
To compare the protein secretion between BMMSCs
and ATMSCs, ELISA was used to investigate the
Figure 2 Proliferation capacity of bone marrow- (BMMSCs) and adipose
tissue (ATMSCs)-derived mesenchymal stem cells in human platelet
lysate-supplemented medium. (A) Cumulative population doublings of
BMMSCs and ATMSCs. (B) Colony-forming unit-fibroblast (CFU-F)
number of BMMSCs and ATMSCs cultivated in human platelet
lysate-supplemented medium at densities of 1,000 per well. All
values are shown as means ± standard deviation; n = 5. *P < 0.05,
**P < 0.01. n.s., not significant.
Table 2 Comparison of the expression of surface markers
of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-
derived mesenchymal stem cells as analyzed by flow
cytometry
Surface markers Expression (%)
BMMSCs (n = 5) ATMSCs (n = 5)
CD13 99.78 ± 0.61 99.17 ± 0.57
CD29 98.36 ± 0.50 98.28 ± 1.04
CD90 99.48 ± 0.43 99.03 ± 0.47
CD105 87.38 ± 0.62 90.31 ± 0.82
HLA-ABC 94.34 ± 1.51 95.94 ± 3.51
CD14 0.23 ± 0.17 0.18 ± 0.20
CD19 0.16 ± 0.08 0.10 ± 0.48
CD34 0.07 ± 0.02 0.05 ± 0.04
CD45 0.08 ± 0.03 0.20 ± 0.15
HLA-DR 0.15 ± 0.11 0.26 ± 0.17
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mokines from ATMSC and BMMSC cultures. Compared
with BMMSCs, ATMSCs secreted significantly greater
amounts of IGF-1 (P < 0.01), bFGF (P < 0.05), and IFN-γ
(P < 0.05). On the other hand, BMMSCs secreted sig-
nificantly greater amounts of SDF-1 (P < 0.01) and HGF
(P < 0.01). However, there were no significant differ-
ences between ATMSCs and BMMSCs for several se-
creted factors, including inflammatory cytokines such
as IL-6 and TNF-α [31], chemokines such as IL-8 [36],
and growth and angiogenic factors such as VEGF [37]
(P > 0.05; Figure 7).
Immunomodulatory factor expression of bone marrow-
and adipose tissue-derived mesenchymal stem cells
When cultured in three different MSC numbers,
ATMSCs in hPL medium exhibited greater IDO activity(all P < 0.01) compared with BMMSCs. However, no sig-
nificantly difference in TGF-β (all P > 0.05) and PGE2
(all P > 0.05) secretion was observed between the two
types of cell (Figure 8).
Discussion
Our findings demonstrate a number of findings. (1)
BMMSCs and ATMSCs expanded in hPL-supplemented
medium exhibit a homogeneous population with similar
fibroblast-like (elongated spindle) morphology. (2) ATMSCs
expanded in hPL-supplemented medium have greater pro-
liferative potential than BMMSCs, while there are no signifi-
cant differences in colony efficiency between the two types
of cells. (3) BMMSCs and ATMSCs in hPL-supplemented
medium reveal very similar expression patterns of surface
markers. (4) BMMSCs expanded in hPL-supplemented
medium possess higher capacity toward osteogenic and
chondrogenic differentiation compared with ATMSCs, while
they both have similar adipogenic differentiation potential.
(5) There are some differences between BMMSCs and
ATMSCs for several secreted proteins, such as cytokines,
growth factors, and chemokines. (6) ATMSCs have more
potent immunomodulatory effects than BMMSCs.
The plastic adherence capacity, surface marker expres-
sion, and multilineage differentiation potential towards
osteoblasts, adipocytes, and chondrocytes have been pro-
posed as minimal criteria to characterize human MSCs
by the International Society for Cellular Therapy [38]. In
the present study, we use hPL for production of MSCs
and analyze all these parameters, and the results favor
the “true MSC nature” of BMMSCs and ATMSCs.
Moreover, the two types of cells exhibit homogeneous
cell populations with a similar morphology and the ex-
pression of surface markers. Many investigators have
demonstrated that MSCs isolated by adherence and
Figure 3 Immunophenotype of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells in human platelet
lysate-supplemented medium. Flow cytometry analysis showed that BMMSCs and ATMSCs consistently stained positive for CD13, CD29, CD90,
CD105, and HLA-ABC and did not react with CD14, CD19, CD34, CD45, and HLA-DR (n = 5; one representative example shown).
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senting heterogeneous populations [39]. In this study,
both BMMSCs and ATMSCs exhibit heterogeneous
morphology with various shapes at the first hPL-
supplemented culture phase, with the morphology
becoming gradually homogeneous with successive pas-
sages. Both types of cells show a similar fibroblast-like
(elongated spindle) morphology in parallel or vortex-like
patterns. The possibility of some resting mature cell
types within the MSC layer after the first step and the
high proliferative rate leads to the culture of successive
passages to obtain a large amount of pure MSCs. In
addition, a possibility is that MSCs in hPL-supplemented
medium are thinner and smaller in morphology and size
compared with those in FBS [23]. In the present study,
BMMSCs and ATMSCs in hPL-supplemented medium
are positive for specific MSC markers (CD13, CD105)
and cell adhesion molecules (CD29, CD90) in agreement
with earlier reports. Furthermore, MSCs are very low
(<0.5%) in all hematopoietic cell markers such as CD14,
CD19, CD34, and CD45, showing that BMMSCs andATMSCs in hPL-supplemented medium have little or no
hematopoietic cell contamination. This result is lower
than the minimal criteria proposed by the International
Society for Cellular Therapy (<2%) and that reported in
FBS-supplemented medium, further suggesting BMMSCs
and ATMSCs in hPL-supplemented medium are nearly
homogeneous populations compared with those in FBS-
supplemented cultures. Interestingly, both types of cells
express HLA-ABC (>90%) but not HLA-DR (<0.5%), con-
sistent with the result under FBS-supplemented culture in
previous reports. Both BMMSCs and ATMSCs reveal very
similar expression patterns of surface markers in agree-
ment with the FBS-based comparative phenotypic analysis
described earlier [40,41].
Multilineage differentiation potential is the most well-
established characteristic of MSCs and thus is consid-
ered the hallmark of these cells. In the present study,
BMMSCs in hPL-supplemented culture exhibit superior
capacity for osteogenic and chondrogenic differentiation
but a similar capacity for adipogenic differentiation when
compared with ATMSCs. According to comparative
Figure 4 Osteogenic differentiation potential of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells in human
platelet lysate-supplemented medium. (A) Alizarin Red staining of BMMSCs and ATMSCs. Magnification × 100. (B) Quantitative assessment of mRNA
expression. Values are shown as mean ± standard deviation; n = 5. *P< 0.05.
Figure 5 Chondrogenic differentiation potential of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells in
human platelet lysate-supplemented medium. (A) Alcian Blue staining of BMMSCs and ATMSCs. Magnification × 100. (B) Quantitative assessment
of mRNA expression. Values are shown as mean ± standard deviation; n = 5. **P < 0.01.
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Figure 6 Adipogenic differentiation potential of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal stem cells in
human platelet lysate-supplemented medium. (A) Oil Red O staining of BMMSCs and ATMSCs. Magnification × 200. (B) Quantitative assessment of
mRNA expression. Values are shown as mean ± standard deviation; n = 5. n.s., not significant.
Figure 7 Quantification of cytokines, growth factors, and chemokines (pg/105 cells) of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived
mesenchymal stem cells. Values are shown as mean ± standard deviation; n = 5. *P < 0.05, **P < 0.01. bFGF, basic fibroblast growth factor;
HGF, hepatocyte growth factor; IFN, interferon; IGF, insulin-like growth factor; IL, interleukin; n.s., not significant; SDF-1, stem cell-derived factor-1;
TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
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Figure 8 Quantification of immunomodulatory factor (pg/mL) of bone marrow- (BMMSCs) and adipose tissue (ATMSCs)-derived mesenchymal
stem cells. Values are shown as mean ± standard deviation; n = 5. *P < 0.01. MSC, mesenchymal stem cell; n.s., not significant; PGE2, prostaglandin
E2; TGF, transforming growth factor.
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ATMSCs in FBS-supplemented medium as described earl-
ier, similar patterns of osteogenic and chondrogenic differ-
entiation are demonstrated between the two types of cells
in FBS-supplemented medium [42]. On the contrary,
ATMSCs have higher adipogenic differentiation potential
than BMMSCs [42], but similar adipogenic differentiation
capacity between the two types of cells in FBS-
supplemented medium is also reported [43]. This may be
related to the different differentiation medium and cell
passage.
Cell-based therapies need viable and ample numbers
of cells for regenerative medicine. In this study, we aim
to optimize MSC culture under xeno-free conditions
and scale up MSCs in preparation for potential clinical
use. Sufficient quantities of MSCs can be scaled up in
hPL-supplemented cultures in 5 passages at a seeding
density of 2,000 cells/cm2, considering that a 75-kg pa-
tient needs approximately 1 to 5 × 106 MSCs per kilo-
gram body weight for transplantation. Based on a
clinical point of view, we therefore suggest that MSCs at
passage 5 be used for evaluation of their characteristics.
For autologous therapies, the cells should be available
soon after injury. In hPL-supplemented cultures,
ATMSCs exhibit a significantly greater number of PDthan BMMSCs, showing the higher proliferative poten-
tial of ATMSCs. Similar patterns were seen in FBS as de-
scribed previously [43], but a previous study has
reported that BMMSCs in FBS show more PD than
ATMSCs in passages 2 to 5 [41]. In addition, BMMSCs
in the hPL yield similar CFU numbers as ATMSCs. A
previous study has reported that the abundance of CFU-
F of ATMSCs in FBS is significantly greater than that of
BMMSCs [39], but another study shows that BMMSCs
form more colonies than ATMSCs in passage 3 [41]. A
possible explanation might be that several rich growth
factors in hPL can stimulate colonies [24].
It has been suggested that the administration of MSC-
derived conditioned medium in experimental models of
acute organ injury is as effective as the administration of
MSCs in some cases [44,45], indicating essential partici-
pation of paracrine mechanisms in diminishing path-
ology. These paracrine factors include different types of
cytokines, such as growth factors, inflammatory cyto-
kines and chemoattractants [46]. Increasing evidence
supports the notion that the mechanism of functional
benefit after MSC implantation is predominantly
dependent on paracrine effects [29-31]. We thus com-
pare the expression of growth factors, cytokines and
chemokines in BMMSCs and ATMSCs expanded in
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source for cell therapy. bFGF, HGF, IGF-1, and VEGF,
several well-demonstrated growth factors in cell-based
tissue repair, are recently shown to be effective in differ-
ent models of acute renal, lung, hepatic, myocardial and
neural injury [29]. However, their in-depth paracrine
mechanisms require further elucidation. Further studies
comparing the importance of these four growth factors
for the repair of different types of tissues are necessary
to determine which growth factor is more effective for
specific applications. BMMSCs secrete higher levels of
HGF, but lower levels of bFGF and IGF-1, and similar
levels of VEGF compared with ATMSCs. The potential
for minimally invasive delivery of MSCs by intravenous
infusion is enormous for therapeutic applications, and
efficient homing of MSCs to the site of injury is critical
for inducing tissue repair and regeneration and would
also reduce the clinical dose of cells required to achieve
a therapeutic effect. Based on the original anatomic loca-
tions of BMMSCs and ATMSCs, they could possibly mi-
grate to different sites after systemic delivery and prove
to be more effective for specific applications. The hom-
ing ability can be attributed to the chemokine expression
of MSCs [29]. It has been suggested that SDF-1, a small
cytokine belonging to the chemokine family, could aug-
ment the mobilization, migration, recruitment, and en-
trapment of MSCs [29]. Experimental and clinical data
have demonstrated that SDF-1 plays an important role
in the mobilization and homing of BMMSCs [47]. In this
study, the level of SDF-1 is significantly higher in
BMMSCs compared with ATMSCs, showing that
BMMSCs have stronger migration capacity. This result
implies that less BMMSCs are required to achieve a
therapeutic effect. A wide range of expression of chemo-
kines and chemokine receptors of MSCs is needed in
further research. The data suggest that BMMSCs and
ATMSCs need to be explored further for distinct thera-
peutic roles. Studying the expression levels of growth
factors, cytokines and chemokines could facilitate our
understanding of their contribution to cell therapy [15].
Clearly, more experiments are required to flesh out the
ideas described in this paper.
The immunomodulation effect of MSCs is to a large
extent mediated via inflammatory cytokines. Several cy-
tokines have been proposed to play a role in the immu-
nomodulation effect of MSCs, including IFN-γ, TNF-α
and IL-6 [45]. It has been demonstrated that IFN-γ is an
important cytokine that regulates the immunomodula-
tory functions of MSCs [48]. Some studies have reported
the influence of media composition or cell source on
MSC immunomodulation [4,48]. However, few studies
to date have examined the effects of cell source based on
hPL. Our comparative study shows a stronger expression
of IFN-γ in ATMSCs, which suggest that ATMSCs mayhave superior immunomodulatory effects. Functional study
demonstrates that ATMSCs exhibit greater IDO activity
compared with BMMSCs, demonstrating that ATMSCs
may have more potent immunomodulatory effects than
BMMSCs, similar to previous results in FBS medium.
Other studies have reported that immunomodulatory-
related cytokines such as PGE2, TGF-β, and IDO secreted
by MSCs, or by immune cells in response to MSCs, play a
major role in MSC-mediated immunomodulation [35].
Clinically, the immunomodulatory properties of MSCs can
be used to enhance engraftment and to reduce the inci-
dence of the graft-versus-host disease after allogeneic
hematopoietic stem cell transplantation. Our data indicates
that ATMSCs might be substituted for BMMSCs for treat-
ment of allogeneic conflicts. Further larger and functional
studies are needed to confirm the prediction (including
other immune-related cytokines and the action on T cells,
natural killer cells, and dendritic cells).
Conclusions
ATMSCs have biological advantages in proliferative cap-
acity, secreted proteins (bFGF, IFN-γ, and IGF-1), and
immunomodulatory effects, but BMMSCs have advan-
tages in osteogenic and chondrogenic differentiation po-
tential and secreted proteins (SDF-1 and HGF); these
biological advantages should be considered systematic-
ally when choosing the MSC source for a specific clinical
application.
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